Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Natera Inc
(NQ:
NTRA
)
89.86
-0.47 (-0.52%)
Streaming Delayed Price
Updated: 11:54 AM EDT, Apr 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Natera Inc
< Previous
1
2
3
4
5
6
Next >
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
April 11, 2024
From
Natera, Inc.
Via
Business Wire
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
April 08, 2024
From
Natera, Inc.
Via
Business Wire
Natera Inc. (NASDAQ: NTRA) Records 52-Week High Friday Morning
April 05, 2024
Via
Investor Brand Network
Natera Inc. (NASDAQ: NTRA) Records 52-Week High Tuesday Morning
January 09, 2024
Via
Investor Brand Network
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
April 05, 2024
From
Natera, Inc.
Via
Business Wire
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
April 01, 2024
From
Natera, Inc.
Via
Business Wire
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
March 18, 2024
From
Natera, Inc.
Via
Business Wire
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
March 14, 2024
From
Natera, Inc.
Via
Business Wire
Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
March 12, 2024
From
Natera, Inc.
Via
Business Wire
Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan
March 07, 2024
From
Natera, Inc.
Via
Business Wire
Natera to Participate in March Investor Conferences
February 29, 2024
From
Natera, Inc.
Via
Business Wire
Natera Reports Fourth Quarter and Full Year 2023 Financial Results
February 28, 2024
From
Natera, Inc.
Via
Business Wire
Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests
February 27, 2024
From
Natera, Inc.
Via
Business Wire
Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer
February 26, 2024
From
Natera, Inc.
Via
Business Wire
Natera Announces Fourth Quarter and Fiscal 2023 Earnings Conference Call
February 20, 2024
From
Natera, Inc.
Via
Business Wire
New Study Validates Signatera™ in Endometrial Cancer
February 05, 2024
From
Natera, Inc.
Via
Business Wire
New Publication Demonstrates Signatera’s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer
January 30, 2024
From
Natera, Inc.
Via
Business Wire
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
January 30, 2024
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END
Via
FinancialNewsMedia
Jury Rules in Favor of Natera in Patent Infringement Lawsuit Against CareDx; Awards $96.3 Million in Damages to Natera in Lost Profits and Past Royalties
January 29, 2024
From
Natera, Inc.
Via
Business Wire
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
January 30, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Nature Medicine Publishes Two Studies Highlighting Signatera’s Clinical Utility in Patients with Gastrointestinal Malignancies
January 25, 2024
From
Natera, Inc.
Via
Business Wire
Natera Acquires Reproductive Health Assets from Invitae
January 22, 2024
From
Natera, Inc.
Via
Business Wire
Natera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signatera’s Clinical Utility in CRC
January 18, 2024
From
Natera, Inc.
Via
Business Wire
Natera Provides Update on Ravgen Trial
January 16, 2024
From
Natera, Inc.
Via
Business Wire
Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues
January 09, 2024
From
Natera, Inc.
Via
Business Wire
Natera to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
December 29, 2023
From
Natera, Inc.
Via
Business Wire
Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics’ RaDaR Test
December 27, 2023
From
Natera, Inc.
Via
Business Wire
NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
December 26, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA
December 21, 2023
From
Natera, Inc.
Via
Business Wire
Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents
December 11, 2023
From
Natera, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.